ProfileGDS5678 / 1430829_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 62% 62% 61% 63% 63% 63% 63% 62% 62% 63% 62% 63% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8462664
GSM967853U87-EV human glioblastoma xenograft - Control 23.71262
GSM967854U87-EV human glioblastoma xenograft - Control 33.7167962
GSM967855U87-EV human glioblastoma xenograft - Control 43.6362361
GSM967856U87-EV human glioblastoma xenograft - Control 53.7079263
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8269363
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8186763
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7528763
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7193562
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6796762
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7337663
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6503262
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8100263
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7362563